Durgical
EN
Open the app

After thyroid cancer surgery: radioiodine, thyroglobulin and TSH targets

  • Follow-up and treatment

After surgery for papillary or follicular cancer, follow-up rests on one blood test, one scan and one dial, and how hard you turn the dial depends on the risk.

Updated

See it in 3D: Thyroid gland · Parathyroid glands

What it is

Differentiated thyroid cancer (papillary and follicular) keeps two features of normal thyroid cells: it takes up iodine and grows under TSH. Follow-up uses both. Radioiodine after total thyroidectomy is selective: often unnecessary in low-risk disease, adjuvant in intermediate risk, and treatment in high-risk or known residual disease. Thyroglobulin, a protein only thyroid cells make, becomes a tumour marker once the gland is gone. Levothyroxine replaces hormone and, in higher-risk disease, keeps TSH low. Neck ultrasound is the main imaging test. The intensity of all three is set by the recurrence risk and then reset by the response to treatment.

What to know

  • Risk of recurrence (low, intermediate, high) is set after surgery from tumour size, spread outside the gland, lymph nodes, vascular invasion, completeness of resection and distant metastases.
  • Radioiodine is not routine for low-risk papillary cancer; it is considered for intermediate risk and given for high risk or iodine-avid residual or metastatic disease.
  • Before radioiodine TSH is raised (by stopping levothyroxine or giving recombinant TSH) and a low-iodine diet is followed, so cells take up more tracer.
  • Thyroglobulin is measured with thyroglobulin antibodies every time: the antibodies, present in about a quarter of patients, make thyroglobulin falsely low; their own trend becomes the marker.
  • Excellent response after total thyroidectomy and radioiodine: suppressed thyroglobulin below about 0.2 ng/mL (or stimulated below about 1 ng/mL), negative antibodies and a clear ultrasound.
  • Usual TSH targets: high-risk or persistent disease below 0.1 mU/L; intermediate about 0.1–0.5 mU/L; low risk or excellent response about 0.5–2 mU/L.
  • Medullary and anaplastic cancers do not take up iodine and do not make thyroglobulin: medullary is followed with calcitonin and CEA.

Step by step

  1. After surgery, stage the tumour and assign a recurrence risk.
  2. Decide on radioiodine by risk; low-risk patients after lobectomy or total thyroidectomy often need none.
  3. Start levothyroxine with a TSH target set by risk.
  4. At 6–12 months measure thyroglobulin, antibodies and TSH, and do a neck ultrasound.
  5. Classify the response (excellent, indeterminate, biochemical incomplete, structural incomplete).
  6. Excellent response: relax the TSH target and space out follow-up.
  7. Rising thyroglobulin or antibodies: ultrasound, then other imaging (whole-body iodine scan, CT, PET when not iodine-avid).

How the risk sets radioiodine and the TSH target

Recurrence riskExampleRadioiodineInitial TSH target
LowSmall intrathyroidal papillary cancer, no nodesUsually not neededAbout 0.5–2 mU/L
IntermediateMinor extension, several involved nodes, aggressive subtypeConsidered (adjuvant)About 0.1–0.5 mU/L
HighGross extension, incomplete resection, distant metastasesGiven (treatment)Below 0.1 mU/L

In the clinic

  • After lobectomy, thyroglobulin is less useful because the remaining lobe makes it; follow-up relies on ultrasound and trends.
  • Long-term TSH suppression causes atrial fibrillation and bone loss, especially in older people and postmenopausal women; targets are relaxed once the response is excellent.
  • Radioiodine can cause dry mouth and salivary gland swelling; pregnancy is avoided for months afterwards.
  • Thyroglobulin is followed with the same laboratory assay, because results from different assays are not interchangeable.

Next step / Initial management

  • Thyroglobulin with thyroglobulin antibodies and TSH, plus neck ultrasound, at 6–12 months and then at intervals set by the response.
  • Levothyroxine to the risk-based TSH target; relax it after an excellent response.
  • Medullary cancer: calcitonin and CEA instead of thyroglobulin, and RET testing with family screening.
  • Refer to endocrinology or the head and neck oncology team every patient after surgery, and promptly for rising thyroglobulin or antibodies, new nodes or structural disease.

Common traps

  • A low thyroglobulin is reassuring on its own: antibodies hide thyroglobulin, so they are checked.
  • Every patient needs radioiodine: low-risk disease gains little and gets the side effects.
  • TSH stays suppressed for life after thyroid cancer: in a low-risk patient with an excellent response it brings AF and osteoporosis without benefit.
  • Medullary cancer is followed with thyroglobulin and treated with radioiodine: it is a C-cell tumour, followed with calcitonin and CEA.
  • A thyroglobulin change between visits means recurrence: if the assay was switched between visits, the change is not a recurrence.

Test yourself

Think of the answer, then tap the question to see it.

Why can thyroglobulin act as a tumour marker after total thyroidectomy and radioiodine?

Only thyroid cells make thyroglobulin. With the gland removed and remnants ablated, measurable thyroglobulin means thyroid cells, usually cancer, are still present.

A patient's thyroglobulin is undetectable, but thyroglobulin antibodies are rising. What does it suggest?

The antibodies make thyroglobulin unreliable; a rising antibody level can itself signal persistent or recurrent disease, so imaging starts with neck ultrasound.

Why is TSH kept low in high-risk papillary cancer but not in low-risk disease?

TSH stimulates growth of thyroid cancer cells. In high-risk disease the benefit outweighs the harm to heart and bone; in low-risk disease it does not.

Why is radioiodine useless after surgery for medullary thyroid cancer?

Medullary cancer comes from C cells, which do not take up iodine; it is followed with calcitonin and CEA.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of endocrinology

Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.

Sources: Papillary Thyroid Carcinoma (StatPearls (NCBI Bookshelf), 2024); Radioactive Iodine Therapy for Thyroid Malignancies (StatPearls (NCBI Bookshelf), 2024); Thyroid Cancer (StatPearls (NCBI Bookshelf), 2023).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.